Mydecine Innovations Group Leads Psychedelic Sector Poll as the Industry Favourite

When it comes to the red-hot sector of psychedelics, there’s no shortage of companies looking to enter the market. Quantity over quality can be an issue for any new industry, with hundreds of companies scrambling to stake their claim. However, it appears that a leader has emerged in the field. According to a recent survey by StrawPoll, Denver based Mydecine Innovations Group (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) ranks as the “favourite” publicly traded company in the psychedelic sector.

This comes as no surprise following Mydecine’s recent landmark progress in psychedelic research across the board. This year has been an important one for the company after successfully completing the first legal import of psychedelic mushrooms to Canada. This marks a major first step in the creation of a comprehensive psychedelic supply chain. In addition to Mydecine’s import capabilities, the company has announced an upcoming clinical trial to study the use of psychedelics in the treatment of PTSD. The first-of-its-kind clinical trial is a major step in the company’s goals to revolutionize the treatment of mental health and wellbeing. These trials are global in scope, with research taking place in 7 countries around the world.

Beyond clinical research and design, Mydecine is also innovating in the world of tech, with the creation of a remote mental health service delivery platform called “Mindleap''. It appears the company has effectively diversified and Mydecine’s CEO, Josh Bartch, attributes their recent success to this diverse set of capabilities.

“One thing about Mydecine that’s incredibly unique is that we’re fully vertically integrated, so as it pertains to psychedelic assisted psychotherapy, we really have an A-Z capability.”

Mydecine is quickly becoming the all-in-one brand in the space of psychedelics. With a recent uplisting to the NEO stock exchange, this novel industry leader has significant potential and will be one to watch moving forward.

This article does not necessarily reflect the opinions of the editors or the management of EconoTimes.